This site is intended for health professionals only

Cyclophosphamide regime reduces graft-versus-host disease after stem-cell transplantation 

A cyclophosphamide-based regime significantly reduces the incidence of graft-versus-host disease (GVHD) after stem-cell transplant compared to standard prophylaxis, according to the findings of a recent phase 3 randomised trial.

Published in the New England Journal of Medicine, the researchers randomly assigned adults with haematologic cancers undergoing allogeneic haematopoietic stem-cell transplantation to receive either cyclophosphamide-tacrolimus-mycophenolate mofetil (experimental prophylaxis) or tacrolimus-methotrexate (standard prophylaxis).

The primary endpoint was set as GVHD-free, relapse-free survival at one year, assessed in a time-to-event analysis. Events were defined as grade III or IV acute GVHD, chronic GVHD warranting systemic immunosuppression, disease relapse or progression and death from any cause.

This comes after a phase 2 trial confirmed that using tacrolimus with mycophenolate mofetil and post-transplantation cyclophosphamide was the most promising intervention for GVHD prophylaxis

Article continues below this sponsored advert
Featured Image
Explore the latest advances in cardiovascular care delivered by renowned experts from recognised Centres of Excellence and other NHS trusts around the UK. Gain CPD, put your burning questions to the experts, and boost your confidence when it comes to care for your patients.
Advertisement

Cyclophosphamide prophylaxis success

In the phase 3 trial, a total of 431 patients with mean age of 64.3 years (60.3% male) were included, of whom 214 were assigned to the experimental regime and followed for a median of 12 months.

The primary outcome was significantly more common in the experimental prophylaxis group (hazard ratio, HR = 0.64, 95% CI 0.49 – 0.83, p = 0.001). In fact, after 12 months, the adjusted GVHD-free, relapse-free survival was 52.7% with the cyclophosphamide regime and only 34.9% with standard prophylaxis. 

In addition, while there was less severe acute or chronic GVHD and a higher level of immunosuppression-free survival at 12 months, there were no substantial differences between the two groups for overall and disease-free survival, relapse and transplantation-related death.

Preventing GVHD

Combining a calcineurin inhibitor such as tacrolimus with methotrexate is standard therapy to prevent GVHD disease following marrow transplantation for leukaemia. Despite this, 30-50% of patients undergoing allogeneic haematopoietic-cell transplantation still develop acute GVHD.

Along with the latest phase 3 trial findings outlined above, emerging data suggests high-dose post-transplantation cyclophosphamide can safely and effectively limit GVHD.






Be in the know
Subscribe to Hospital Pharmacy Europe newsletter and magazine

x